MDT
88.96
+0.59%↑
VEEV
226.47
-0.52%↓
A
115.98
+2.05%↑
HQY
88.73
+1.89%↑
PDCO
31.27
+0.06%↑
MDT
88.96
+0.59%↑
VEEV
226.47
-0.52%↓
A
115.98
+2.05%↑
HQY
88.73
+1.89%↑
PDCO
31.27
+0.06%↑
MDT
88.96
+0.59%↑
VEEV
226.47
-0.52%↓
A
115.98
+2.05%↑
HQY
88.73
+1.89%↑
PDCO
31.27
+0.06%↑
MDT
88.96
+0.59%↑
VEEV
226.47
-0.52%↓
A
115.98
+2.05%↑
HQY
88.73
+1.89%↑
PDCO
31.27
+0.06%↑
MDT
88.96
+0.59%↑
VEEV
226.47
-0.52%↓
A
115.98
+2.05%↑
HQY
88.73
+1.89%↑
PDCO
31.27
+0.06%↑
24h
Current
Min
Max
Income | -2.5M -36M |
---|---|
Sales | 8.3M 12M |
EPS | -0.69 |
Profit margin | -296.762 |
Employees | 59 |
EBITDA | 13M -17M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +190.99% upside |
Next Earnings | 6 maj 2025 |
---|
Market Cap | -7.3M 425M |
---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
5 sie 2024, 11:25 UTC
Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 22.29 USD 190.99%
High 25 USD
Low 18 USD
Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
8 ratings
8
Buy
0
Hold
0
Sell
Based on 8 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$